| |  Online-Ressource |
|---|
| Verfasst von: | Krämer, Isabelle [VerfasserIn]  |
|---|
| | König, Laila [VerfasserIn] |
|---|
| | Luft, Thomas [VerfasserIn] |
|---|
| | Hegenbart, Ute [VerfasserIn] |
|---|
| | Schönland, Stefan [VerfasserIn] |
|---|
| | Eichkorn, Tanja [VerfasserIn] |
|---|
| | Stadtherr, Peter [VerfasserIn] |
|---|
| | Selberg, Lorenz [VerfasserIn] |
|---|
| | Müller-Tidow, Carsten [VerfasserIn] |
|---|
| | Dreger, Peter [VerfasserIn] |
|---|
| Titel: | Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma |
|---|
| Verf.angabe: | Isabelle Krämer, Laila König, Thomas Luft, Ute Hegenbart, Stefan Schönland, Tanja Eichkorn, Peter Stadtherr, Lorenz Selberg, Carsten Müller-Tidow and Peter Dreger |
|---|
| E-Jahr: | 2025 |
|---|
| Jahr: | 13 February 2025 |
|---|
| Umfang: | 6 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Online veröffentlicht: 13. Februar 2025 ; Gesehen am 24.07.2025 |
|---|
| Titel Quelle: | Enthalten in: Bone marrow transplantation |
|---|
| Ort Quelle: | London : Springer Nature, 1997 |
|---|
| Jahr Quelle: | 2025 |
|---|
| Band/Heft Quelle: | 60(2025), 5 vom: Feb., Seite 581-586 |
|---|
| ISSN Quelle: | 1476-5365 |
|---|
| Abstract: | Allogeneic hematopoietic cell transplantation (alloHCT) is an effective treatment for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL), but the contribution of the conditioning regimen is still unclear. Here we present a retrospective single-center study using conditioning with intermediate-dose total body irradiation (TBI) and fludarabine for alloHCT in PTCL. Forty-seven patients underwent alloHCT for PTCL between 2010 and 2023 after conditioning with fludarabine and intermediate-dose TBI (8 Gy in 87% of the cases). In most patients alloHCT was administered as part of second-line therapy, in 22 (47%) patients after having been primary refractory, and 21 (45%) of the patients were chemoresistant at alloHCT. With a median follow-up of 5.5 years, 5-year progression-free survival (PFS), overall survival, relapse incidence, and non-relapse mortality were 61%, 65%, 24%, and 15%, respectively. The 5-year PFS of patients transplanted with stable disease and progressive disease was 57% and 26%, respectively. Of 11 relapses, only 2 (18%) occurred beyond 6 months post transplant, and no relapse was observed after onset of chronic graft-versus-host disease. AlloHCT with intermediate-dose TBI/fludarabine conditioning is associated with a favorable toxicity/efficacy profile and can provide durable survival in a substantial fraction of patients with PTCL including those with poorly controlled disease at transplant. |
|---|
| DOI: | doi:10.1038/s41409-025-02522-4 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.1038/s41409-025-02522-4 |
|---|
| | kostenfrei: Volltext: https://www.nature.com/articles/s41409-025-02522-4 |
|---|
| | DOI: https://doi.org/10.1038/s41409-025-02522-4 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Stem-cell therapies |
|---|
| | T-cell lymphoma |
|---|
| K10plus-PPN: | 1931686734 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma / Krämer, Isabelle [VerfasserIn]; 13 February 2025 (Online-Ressource)
